200 related articles for article (PubMed ID: 2053304)
1. [Serum beta 2-microglobulin in multiple myeloma. I. Relation to selected indicators, clinical stage and disease prognosis].
Scudla V; Budíková M; Fischerová E; Raska I; Vavrdová V
Vnitr Lek; 1991 Apr; 37(4):342-51. PubMed ID: 2053304
[TBL] [Abstract][Full Text] [Related]
2. [Soluble interleukin-6 receptors in the serum in multiple myeloma].
Scudla V; Kubalová D; Bacovský J; Lukes J; Vavrdová V
Cas Lek Cesk; 1996 Nov; 135(22):719-22. PubMed ID: 8998823
[TBL] [Abstract][Full Text] [Related]
3. [Serum interleukin-6 in multiple myeloma: I. Relation to selected laboratory indicators of disease].
Scudla V; Bacovský J; Budíková M; Klímová D; Faltýnek L
Vnitr Lek; 1995 Sep; 41(9):593-8. PubMed ID: 7483349
[TBL] [Abstract][Full Text] [Related]
4. [Clinical importance of the paraprotein index in multiple myeloma].
Papajík T; Bacovský J; Zadrazil J; Budíková M; Faltýnek L; Scudla V
Vnitr Lek; 1994 Aug; 40(8):502-5. PubMed ID: 7941436
[TBL] [Abstract][Full Text] [Related]
5. [Relation of the soluble cytoadhesion molecules VCAM-1 and ICAM-1 to selected clinical and laboratory indicators in multiple myeloma].
Scudla V; Budíková M; Bacovský J; Ordeltová M; Opíchalová D; Heincová V
Vnitr Lek; 1999 Oct; 45(10):583-90. PubMed ID: 10951865
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of correction of serum beta 2-microglobulin levels for serum creatinine in multiple myeloma.
Scudla V; Vavrdová V; Budíková M; Indrák K
Acta Univ Palacki Olomuc Fac Med; 1991; 131():257-64. PubMed ID: 1840347
[TBL] [Abstract][Full Text] [Related]
7. [Serum beta-2-microglobulin in multiple myeloma. Practical value].
Bataille R; Magub M; Sany J; Donadio D; Izarn P; Grenier J; Suquet P
Rev Rhum Mal Osteoartic; 1981 Mar; 48(3):235-40. PubMed ID: 6164091
[TBL] [Abstract][Full Text] [Related]
8. [Serum thymidine kinase in multiple myeloma: I. Relation to selected laboratory indicators in the disease].
Scudla V; Bacovský J; Papajík T; Budíková M; Srovnalík K
Vnitr Lek; 1994 Mar; 40(3):151-6. PubMed ID: 8184566
[TBL] [Abstract][Full Text] [Related]
9. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count.
Perosa F; Minoia C; Favoino E; Prete M; Dammacco F
Blood Cells Mol Dis; 2009; 42(1):71-6. PubMed ID: 18996035
[TBL] [Abstract][Full Text] [Related]
10. [Prognostic analysis and assessment on the clinical staging systems of multiple myeloma--a report of 206 cases].
Tao ZF; Fu WJ; Chen YB; Yuan ZG; Wang DX; Hou J
Ai Zheng; 2006 Apr; 25(4):461-4. PubMed ID: 16613681
[TBL] [Abstract][Full Text] [Related]
11. Stratification of multiple myeloma according to serum beta 2-microglobulin and serum albumin levels.
Scudla V; Budíková M; Fischerová E; Zadrazil J; Indrák K
Acta Univ Palacki Olomuc Fac Med; 1991; 130():201-12. PubMed ID: 1838869
[TBL] [Abstract][Full Text] [Related]
12. [Prognostic importance of beta-2-microglobulin in multiple myeloma].
Avilés A; Zepeda G; Guzmán R; Talavera A; García EL; Díaz-Maqueo JC
Rev Invest Clin; 1992; 44(2):215-20. PubMed ID: 1439309
[TBL] [Abstract][Full Text] [Related]
13. Serum beta 2 microglobulin in multiple myeloma and related plasma cell dyscrasias.
Pasquini E; Tiraferri E; Fattori PP; Fabbri I; Gobbi M
Haematologica; 1987; 72(1):17-21. PubMed ID: 3108090
[No Abstract] [Full Text] [Related]
14. [Serum beta 2-microglobulin in multiple myeloma. II. Its significance in monitoring the disease].
Scudla V; Budíková M; Fischerová E; Raska I; Vavrdová V
Vnitr Lek; 1991 May; 37(5):479-87. PubMed ID: 1842146
[TBL] [Abstract][Full Text] [Related]
15. [The prognostic significance of the beta 2-microglobulin level of the blood serum in multiple myeloma patients].
Lubo-Lesnichenko IF; Bessmel'tsev SS; Abdulkadyrov KM; Blinov MN; Stel'mashenko LV
Ter Arkh; 1996; 68(10):28-31. PubMed ID: 9026938
[TBL] [Abstract][Full Text] [Related]
16. [Importance of selected laboratory indicators in the differential diagnosis and monitoring of multiple myeloma].
Maisnar V; Tousková M; Malý J; Krejsek J; Kmonícek M; Kopecký O
Vnitr Lek; 2002 Apr; 48(4):290-7. PubMed ID: 12061177
[TBL] [Abstract][Full Text] [Related]
17. [Importance of determining the propidium-iodide index of plasmacytes in multiple myeloma. I. Relation to selected laboratory indicators of the disease].
Scudla V; Ordeltová M; Spidlová A; Bacovský J; Kurasová J; Vránová M
Vnitr Lek; 1999 Jun; 45(6):331-5. PubMed ID: 11045167
[TBL] [Abstract][Full Text] [Related]
18. [Serum ferritin and beta-2-microglobulin in multiple myeloma].
Linkesch W; Ludwig H
Acta Med Austriaca; 1982; 9(5-6):227-31. PubMed ID: 6187172
[TBL] [Abstract][Full Text] [Related]
19. Total soluble HLA class I and soluble HLA-G in multiple myeloma and monoclonal gammopathy of undetermined significance.
Leleu X; Le Friec G; Facon T; Amiot L; Fauchet R; Hennache B; Coiteux V; Yakoub-Agha I; Dubucquoi S; Avet-Loiseau H; Mathiot C; Bataille R; Mary JY;
Clin Cancer Res; 2005 Oct; 11(20):7297-303. PubMed ID: 16243800
[TBL] [Abstract][Full Text] [Related]
20. Serum ferritin and beta 2-microglobulin in patients with multiple myeloma.
Linkesch W; Ludwig H
Cancer Detect Prev; 1983; 6(1-2):297-301. PubMed ID: 6192921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]